{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:34:38Z","timestamp":1793331278370,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.tvjl.2025.106412","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:06:42Z","timestamp":1754424402000},"page":"106412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Canagliflozin: Pharmacokinetics, tolerability and glucose\/insulin effects of supratherapeutic doses in healthy horses"],"prefix":"10.1016","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-3795","authenticated-orcid":false,"given":"Peter","family":"Michanek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Br\u00f6jer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Lillieh\u00f6\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrine","family":"Fjordbakk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Erkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minerva","family":"L\u00f6wgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hedeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Ekstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2025.106412_bib1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.tvjl.2007.07.003","article-title":"Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies","volume":"174","author":"Asplin","year":"2007","journal-title":"The Veterinary Journal"},{"issue":"1","key":"10.1016\/j.tvjl.2025.106412_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"Journal of Statistical Software"},{"key":"10.1016\/j.tvjl.2025.106412_bib3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tvjl.2008.02.029","article-title":"Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies","volume":"179","author":"Carter","year":"2009","journal-title":"The Veterinary Journal"},{"key":"10.1016\/j.tvjl.2025.106412_bib4","series-title":"In: Journal of Veterinary Internal Medicine","first-page":"780","article-title":"Effects of levothyroxine sodium on body condition, blood measures of metabolic status,and glucose dynamics in horses with equinemetabolic syndrome (EMS)","author":"Chameroy","year":"2010"},{"key":"10.1016\/j.tvjl.2025.106412_bib5","article-title":"The effect of pre-dosing with metformin on the insulin response to oral sugar in insulin-dysregulated horses","author":"Colmer","year":"2023","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2025.106412_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5414\/CP202218","article-title":"Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.tvjl.2025.106412_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jvim.15423","article-title":"ECEIM consensus statement on equine metabolic syndrome","volume":"33","author":"Durham","year":"2019","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2025.106412_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2746\/042516408X273648","article-title":"The effect of metformin on measurements of insulin sensitivity and \u03b2 cell response in 18horses and ponies with insulin resistance","volume":"40","author":"Durham","year":"2008","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2025.106412_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2460\/javma.228.9.1383","article-title":"Physical characteristics, blood hormone concentrations, and plasma lipid concentrations in obese horses with insulin resistance","volume":"228","author":"Frank","year":"2006","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.tvjl.2025.106412_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.2042-3306.1983.tb01826.x","article-title":"Relationship between condition score, physical measurements and body fat percentage in mares","volume":"15","author":"Henneke","year":"1983","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2025.106412_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5455\/OVJ.2022.v12.i4.14","article-title":"Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis","volume":"12","author":"Kellon","year":"2022","journal-title":"Open Veterinary Journal"},{"key":"10.1016\/j.tvjl.2025.106412_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5455\/OVJ.2023.v13.i3.14","article-title":"Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors","volume":"13","author":"Kellon","year":"2023","journal-title":"Open Veterinary Journal"},{"key":"10.1016\/j.tvjl.2025.106412_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2746\/042516409X475779","article-title":"Equine laminitis: induced by 48 h hyperinsulinaemia in standardbred horses","volume":"42","author":"de Laat","year":"2010","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2025.106412_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jevs.2019.102797","article-title":"Pharmacodynamic effects of pioglitazone on high molecular weight adiponectin concentrations and insulin response after oral sugar in equids","volume":"82","author":"Legere","year":"2019","journal-title":"Journal of Equine Veterinary Science"},{"key":"10.1016\/j.tvjl.2025.106412_bib15","unstructured":"Lenth, R.V., 2024. emmeans: Estimated Marginal Means, aka Least-Squares Means, 1.10.5 ed."},{"key":"10.1016\/j.tvjl.2025.106412_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jcjd.2016.03.007","article-title":"Comparison of Second-Phase insulin secretion derived from standard and modified low-dose graded glucose infusion tests","volume":"40","author":"Lin","year":"2016","journal-title":"The Canadian Journal of Diabetes"},{"key":"10.1016\/j.tvjl.2025.106412_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/jvim.16906","article-title":"Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: a randomized, placebo-controlled, double-blind, study","author":"Lindase","year":"2023","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2025.106412_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cveq.2007.08.001","article-title":"Polyuria and polydipsia in horses","volume":"23","author":"McKenzie","year":"2007","journal-title":"Veterinary Clinics of North America Equine Practice"},{"key":"10.1016\/j.tvjl.2025.106412_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s12917-019-1811-2","article-title":"The efficacy and safety of velagliflozin over 16\u2009weeks as a treatment for insulin dysregulation in ponies","volume":"15","author":"Meier","year":"2019","journal-title":"BMC Veterinary Research"},{"key":"10.1016\/j.tvjl.2025.106412_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203655","article-title":"The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies","volume":"13","author":"Meier","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.tvjl.2025.106412_bib21","article-title":"Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses","author":"Menzies-Gow","year":"2024","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"10.1016\/j.tvjl.2025.106412_bib22","article-title":"Pharmacokinetics and alterations in glucose and insulin levels after a single dose of canagliflozin in healthy Icelandic horses","author":"Michanek","year":"2024","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"10.1016\/j.tvjl.2025.106412_bib23","unstructured":"Simulations Plus, 2024. Pkanalix 2024R1, Lancaster, CA, USA."},{"key":"10.1016\/j.tvjl.2025.106412_bib24","unstructured":"R Core Team, 2024. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria."},{"key":"10.1016\/j.tvjl.2025.106412_bib25","unstructured":"Reiche, D.B., Mohren, N., Johnston, L., Somerville, B., Voth, R.K., 2015. TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS, In: \u3008https:\/\/data.epo.org\/publication-server\/rest\/v1.0\/publication-dates\/20200513\/patents\/EP3125882NWB1\/document.html\u3009. Boehringer Ingelheim Vetmedica GmbH."},{"key":"10.1016\/j.tvjl.2025.106412_bib26","unstructured":"Signorell, A., 2024. DescTools: Tools for Descriptive Statistics, 0.99.57 ed."},{"key":"10.1016\/j.tvjl.2025.106412_bib27","series-title":"nlme: Linear and Nonlinear Mixed Effects Models, 3.1-166 ed","author":"Pinheiro","year":"2023"},{"key":"10.1016\/j.tvjl.2025.106412_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1939-1676.2011.0681.x","article-title":"Effects of the Insulin-Sensitizing drug pioglitazone and lipopolysaccharide administration on insulin sensitivity in horses","volume":"25","author":"Suagee","year":"2011","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2025.106412_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/eve.13738","article-title":"Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series","volume":"35","author":"Sundra","year":"2023","journal-title":"Equine Veterinary Education"},{"key":"10.1016\/j.tvjl.2025.106412_bib30","article-title":"Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia-associated laminitis","author":"Sundra","year":"2024","journal-title":"Equine Veterinary Education"},{"key":"10.1016\/j.tvjl.2025.106412_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2024.106894","article-title":"Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: a retrospective case series","volume":"90","author":"Sundra","year":"2025","journal-title":"Domestic Animal Endocrinology"},{"key":"10.1016\/j.tvjl.2025.106412_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon","year":"2024","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.tvjl.2025.106412_bib33","doi-asserted-by":"crossref","unstructured":"Wickham, H., 2016. ggplot2: Elegant Graphics for Data Analysis.","DOI":"10.1007\/978-3-319-24277-4_9"}],"updated-by":[{"DOI":"10.1016\/j.tvjl.2026.106922","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000}}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023325001169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023325001169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:19:35Z","timestamp":1772882375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023325001169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S1090023325001169"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2025.106412","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canagliflozin: Pharmacokinetics, tolerability and glucose\/insulin effects of supratherapeutic doses in healthy horses","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2025.106412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106412"}}